Asian Pacific Journal of Cancer Prevention

Asian Pacific Journal of Cancer Prevention (아시아태평양암예방학회)
권호 표지
DOI QR코드

DOI QR Code

Comparative Analysis of the Efficacy and Safety of Oxaliplatin Plus 5-Fluorouracil/Leucovorin (Modified FOLFOX6) with Advanced Gastric Cancer Patients having a Good or Poor Performance Status

  • Hacibekiroglu, Ilhan (Department of Medical Oncology, Faculty of Medicine, Trakya University) ;
  • Kodaz, Hilmi (Department of Medical Oncology, Faculty of Medicine, Trakya University) ;
  • Erdogan, Bulent (Department of Medical Oncology, Faculty of Medicine, Trakya University) ;
  • Turkmen, Esma (Department of Medical Oncology, Faculty of Medicine, Trakya University) ;
  • Esenkaya, Asim (Department of Radiology, Faculty of Medicine, Trakya University) ;
  • Uzunoglu, Sernaz (Department of Medical Oncology, Faculty of Medicine, Trakya University) ;
  • Cicin, Irfan (Department of Medical Oncology, Faculty of Medicine, Trakya University)
  • Published : 2015.04.03
Download PDF
⟨ Previous Next ⟩

Abstract

Background: Combination chemotherapy of 5 fluorouracil (5-FU) and leucovorin (LV) with oxaliplatin, mainly FOLFOX regimens, has shown considerable antitumor activity and a tolerable toxicity profile in gastric cancer. The goal of this study was to retrospectively compare the efficacy and toxicity of modified FOLFOX-6 (mFOLFOX6) regimen in advanced gastric cancer (AGC) patients with good and poor performance status (PS). Materials and Methods: AGC patients receiving the mFOLFOX6 regimen including oxaliplatin $85mg/m^2$, bolus of 5-FU $400mg/m^2$ and LV $400mg/m^2$ on the first day, followed by $2400mg/m^2$ of 5- FU as a continious infusion over 46 hour for first-line treatment were eligible for the study. Results: A total 58 patients with a median age of 59.5 (32-81) were included. The median follow up of the study was 9.2 months. Thirty patients (51.7%) with an ECOG PS 0-1 were assigned to the good PS arm, while 28 patients (48.3%) with ECOG PS 2 were in the poor PS arm. Overall response rates were 36.6 and 28.8%, respectively (p=0.91). Median PFS was 6.7 and 6.3 months in good PS and poor PS arms (p=0.50) and median OS was 9.6 and 10.4 months (p=0.55). As compared with good PS arm, poor PS arm was associated with more grade 3-4 neutropenia and anemia. Dose reduction and dose delays were also significantly higher. Conclusions: In this study, mFOLFOX6 was similarly effective in both arms. Although hematologic toxicity was significantly higher in patients with poor PS, it remained manageable. Our results suggest that this regimen may be an effective treatment option for AGC patients with poor PS.

Keywords

References

  1. Al-Batran SE, Atmaca A, Hegewisch-Becker S, et al (2004). Phase II trial of biweekly infusional fluorouracil, folinic acid, and oxaliplatin in patients with advanced gastric cancer. J Clin Oncol, 22, 658-63. https://doi.org/10.1200/JCO.2004.07.042
  2. Bernards N, Creemers GJ, Nieuwenhuijzen GA, et al (2013). No improvement in median survival for patients with metastatic gastric cancer despite increased use of chemotherapy. Ann Oncol, 24, 3056-60. https://doi.org/10.1093/annonc/mdt401
  3. Bleiberg H, de Gramont A (1998). Oxaliplatin plus 5-fluorouracil: clinical experience in patients with advanced colorectal cancer. Semin Oncol, 25, 32-9.
  4. Bilici A, Selcukbiricik F, Demin N, et al (2015). Modified docetaxel and cisplatin in combination with capecitabine (DCX) as a first-line treatment in HER2-negative advanced gastric cancer. Asian Pac J Cancer Prev, 15, 8661-6
  5. Cavanna L, Artioli F, Codignola C, et al (2006). Oxaliplatin in combination with 5-fluorouracil (5-FU) and leucovorin (LV) in patients with metastatic gastric cancer (MGC). Am J Clin Oncol, 29, 371-5. https://doi.org/10.1097/01.coc.0000221358.57089.f2
  6. Chang YR, Han DS, Kong SH, et al (2012). The value of palliative gastrectomy in gastric cancer with distant metastasis. Ann Surg Oncol, 19, 1231-9. https://doi.org/10.1245/s10434-011-2056-x
  7. Chau I, Norman AR, Cunningham D, et al (2004). Multivariate prognostic factor analysis in locally advanced and metastatic esophago-gastric cancer--pooled analysis from three multicenter, randomized, controlled trials using individual patient data. J Clin Oncol, 22, 2395-403. https://doi.org/10.1200/JCO.2004.08.154
  8. Cirillo M, Venturini M, Ciccarelli L, et al (2009). Clinician versus nurse symptom reporting using the National Cancer Institute-Common Terminology Criteria for Adverse Events during chemotherapy: results of a comparison based on patient's self-reported questionnaire. Ann Oncol, 20, 1929-35. https://doi.org/10.1093/annonc/mdp287
  9. de Gramont A, Figer A, Seymour M, et al (2000). Leucovorin and fluorouracil with or without oxaliplatin as first-line treatment in advanced colorectal cancer. J Clin Oncol, 18, 2938-47.
  10. De Vita F, Orditura M, Matano E, et al (2005). A phase II study of biweekly oxaliplatin plus infusional 5-fluorouracil and folinic acid (FOLFOX-4) as first-line treatment of advanced gastric cancer patients. Br J Cancer, 92, 1644-9. https://doi.org/10.1038/sj.bjc.6602573
  11. Eisenhauer EA, Therasse P, Bogaerts J, et al (2009). New response evaluation criteria in solid tumours: revised RECIST guideline (version 1.1). Eur J Cancer, 45, 228-47. https://doi.org/10.1016/j.ejca.2008.10.026
  12. Ferlay J, Soerjomataram I, Dikshit R, et al (2014). Cancer incidence and mortality worldwide: Sources, methods and major patterns in GLOBOCAN 2012. Int J Cancer.
  13. Glimelius B, Ekstrom K, Hoffman K, et al (1997). Randomized comparison between chemotherapy plus best supportive care with best supportive care in advanced gastric cancer. Ann Oncol, 8, 163-8. https://doi.org/10.1023/A:1008243606668
  14. Hwang WS, Chao TY, Lin SF, et al (2008). Phase II study of oxaliplatin in combination with continuous infusion of 5-fluorouracil/leucovorin as first-line chemotherapy in patients with advanced gastric cancer. Anticancer Drugs, 19, 283-8. https://doi.org/10.1097/CAD.0b013e3282f3fd17
  15. Kim HS, Kim JH, Kim HJ, et al (2012). Oxaliplatin, 5-fluorouracil and leucovorin (modified FOLFOX-6) as first-line chemotherapy for advanced gastric cancer patients with poor performance status. Oncol Lett, 3, 425-8.
  16. Lee HH, Hur H, Kim SH, et al (2010). Outcomes of modified FOLFOX-6 as first line treatment in patients with advanced gastric cancer in a single institution; retrospective analysis. Cancer Res Treat, 42, 18-23. https://doi.org/10.4143/crt.2010.42.1.18
  17. Liu J, Huang XE, Feng JF (2014). Further study on pemetrexed based chemotherapy in treating patients with advanced gastric cancer (AGC). Asian Pac J Cancer Prev, 15, 6587-90 https://doi.org/10.7314/APJCP.2014.15.16.6587
  18. Lordick F, Lorenzen S, Stollfuss J, et al (2005). Phase II study of weekly oxaliplatin plus infusional fluorouracil and folinic acid (FUFOX regimen) as first-line treatment in metastatic gastric cancer. Br J Cancer, 93, 190-4. https://doi.org/10.1038/sj.bjc.6602697
  19. Louvet C, Andre T, Tigaud JM, et al (2002). Phase II study of oxaliplatin, fluorouracil, and folinic acid in locally advanced or metastatic gastric cancer patients. J Clin Oncol, 20, 4543-8. https://doi.org/10.1200/JCO.2002.02.021
  20. Luo HY, Xu RH, Zhang L, et al (2008). A pilot study of oxaliplatin, fluorouracil and folinic acid (FOLFOX-6) as first-line chemotherapy in advanced or recurrent gastric cancer. Chemotherapy, 54, 228-35. https://doi.org/10.1159/000140467
  21. Miller RJ (1989). The role of chemotherapy in the hospice patient. A problem of definition. Am J Hosp Care, 6, 19-26.
  22. Pyrhonen S, Kuitunen T, Nyandoto P, et al (1995). Randomised comparison of fluorouracil, epidoxorubicin and methotrexate (FEMTX) plus supportive care with supportive care alone in patients with non-resectable gastric cancer. Br J Cancer, 71, 587-91. https://doi.org/10.1038/bjc.1995.114
  23. Shitara K, Muro K, Matsuo K, et al (2009). Chemotherapy for patients with advanced gastric cancer with performance status 2. Gastrointest Cancer Res, 3, 220-4.
  24. Siegel R, Ma J, Zou Z, et al (2014). Cancer statistics, 2014. CA Cancer J Clin, 64, 9-29. https://doi.org/10.3322/caac.21208
  25. Sumpter K, Harper-Wynne C, Cunningham D, et al (2005). Report of two protocol planned interim analyses in a randomised multicentre phase III study comparing capecitabine with fluorouracil and oxaliplatin with cisplatin in patients with advanced oesophagogastric cancer receiving ECF. Br J Cancer, 92, 1976-83. https://doi.org/10.1038/sj.bjc.6602572
  26. Wagner AD, Grothe W, Haerting J, et al (2006). Chemotherapy in advanced gastric cancer: a systematic review and meta-analysis based on aggregate data. J Clin Oncol, 24, 2903-9. https://doi.org/10.1200/JCO.2005.05.0245

Cited by

  1. Association of baseline patient characteristics with adjuvant chemotherapy toxicities in stage III colorectal cancer patients vol.35, pp.10, 2018, https://doi.org/10.1007/s12032-018-1188-2